Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedPointe To Seek Fluorofelbamate Partner After Carter-Wallace Acquisition

Executive Summary

MedPointe will likely seek a development partner for the anti-epileptic fluorofelbamate after the company acquires Carter-Wallace's healthcare business.
Advertisement

Related Content

Soma Tablet Particles Show No Adverse Health Effects, MedPointe Tells FDA
Soma Tablet Particles Show No Adverse Health Effects, MedPointe Tells FDA
Carter-Wallace Felbatol (correction)
Carter-Wallace Felbatol (correction)
Carter-Wallace Felbatol Successor Is Part Of R&D Rebuilding Under Wild
Carter-Wallace Felbatol Successor Is Part Of R&D Rebuilding Under Wild
Advertisement
UsernamePublicRestriction

Register

PS038407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel